In a follow-up to our previously reported genome-wide association study of cutaneous basal cell carcinoma (BCC) 1 , we describe here several new susceptibility variants. SNP rs11170164, encoding a G138E substitution in the keratin 5 (KRT5) gene, affects risk of BCC (OR ¼ 1.35, P ¼ 2.1 Â 10 À9 ). A variant at 9p21 near CDKN2A and CDKN2B also confers susceptibility to BCC (rs2151280 [C] ; OR ¼ 1.19, P ¼ 6.9 Â 10 À9 ), as does rs157935 [T] at 7q32 near the imprinted gene KLF14 (OR ¼ 1.23, P ¼ 5.7 Â 10 À10 ). The effect of rs157935 [T] is dependent on the parental origin of the risk allele. None of these variants were found to be associated with melanoma or fair-pigmentation traits. A melanoma-and pigmentation-associated variant in the SLC45A2 gene, L374F, is associated with risk of both BCC and squamous cell carcinoma. Finally, we report conclusive evidence that rs401681 [C] in the TERT-CLPTM1L locus confers susceptibility to BCC but protects against melanoma.
Cutaneous BCC is the most common cancer among people of European ancestry. The primary environmental risk factor for BCC is sun exposure, but genetics also has a substantial role. Some of the sequence variants that confer susceptibility seem to operate through their association with fair-pigmentation traits, common among Europeans, resulting in reduced protection from the damaging effects of UV radiation. Other sequence variants have no obvious role in pigmentation or UV susceptibility but instead seem to operate in the contexts of growth and differentiation of the basal layers of the skin [1] [2] [3] [4] .
We previously conducted a genome-wide SNP association scan (GWAS) for common BCC risk variants. We discovered susceptibility variants at 1p36, 1q42 and 5p15 (TERT-CLPTM1L) 1, 4 . Here we investigated 30 more high-ranking SNPs from the GWAS by genotyping them in an additional 903 Icelandic BCC cases and a casecontrol sample from Eastern Europe. SNPs at three loci were then selected for further investigation: rs11170164 in the keratin 5 (KRT5) gene, rs2151280 near the CDKN2A and CDKN2B genes and rs157935 on 7q32. These SNPs were further genotyped in case-control samples from Spain and the United States and proved to be significantly (P o 6 Â 10 À7 ) associated with BCC risk. An overview of the samples used in the study is presented in Supplementary Table 1 ; data for the 27 SNPs that were not studied further at this stage are listed in Supplementary Table 2 . We also examined whether the three new BCC variants are concomitantly associated with squamous cell carcinoma (SCC), cutaneous melanoma (CM) and fair-pigmentation traits. We then used the same approach to investigate recently described variants in SLC45A2 and TERT-CLPTM1L [4] [5] [6] .
After genotyping the Icelandic and non-Icelandic replication samples, a combined OR of 1.35 (P ¼ 2.1 Â 10 À9 ) was detected for rs11170164 [A] , specifying a G138E substitution in KRT5 ( Table 1) . Because this P value is below the Bonferroni threshold for genomewide significance (P ¼ 1.6 Â 10 À7 ) and the association replicated consistently in different populations (OR ¼ 1.49, P ¼ 4.6 Â 10 À6 in the non-Icelandic samples), we conclude that the G138E substitution confers susceptibility to BCC. The KRT5 gene product K5 and its heterodimeric partner K14 are the major keratins of basal epithelial cells, forming the intermediate filament cytoskeletal network. This network is crucial for the structural integrity of the basal cell layer 7 .
Some sequence variants, particularly those controlling pigmentation trait variation, simultaneously affect risks of BCC, SCC and CM 1, 3 . Combining the Icelandic and US data for SCC revealed an OR Table 1 ). Despite the large sample size, there was no evidence to indicate that G138E affects risk of CM ( Table 1) . We looked for evidence of association with eye color, hair color, freckles and sun sensitivity using self-reported data from approximately 6,200 Icelanders 8, 9 . There was no evidence of an association with any pigmentation trait (Supplementary Table 3 ) nor was there any difference in frequency of rs11170164[A] between individuals with BCC lesions at typically sun-exposed (head and arms) versus those with lesions at unexposed (trunk and legs) body sites (P ¼ 0.09). Together, these data suggest that the G138E variant affects BCC susceptibility through mechanisms other than those related to obvious pigmentation characteristics. We expanded our investigation of KRT5 to include six more exonic polymorphisms that are common in Europeans, including three additional nonsynonymous SNPs (nsSNPs). Two of the nsSNPs showed nominally significant signals: rs641615 (D197E) and rs11549949 (G543S) (Supplementary Table 4 ). For both, BCC risk was associated with the reference allele. The signal from G543S lost significance when multiple testing was taken into consideration. D197E gave a combined OR of 1.21 (P ¼ 2.2 Â 10 À5 ) ( Table 2) . SNP rs641615 is in the same linkage disequilibrium (LD) block as rs11170164 (G138E) although the frequencies differ markedly (D¢ ¼ 1.00, r 2 ¼ 0.03). In a multivariate analysis, the signal from D197E remained significant when adjusted for the effect of G138E ( Table 2 ), indicating that the two substitutions affect risk independently. However, it remains possible that another unobserved variant that is in LD with both substitutions is responsible for the BCC susceptibility. The signal from G543S also retained its nominal significance when adjusted for the joint effects of G138E and D197E (Supplementary Table 4) , raising the possibility, as yet unproven, of a third independent risk variant in KRT5.
Gly138 is highly conserved in vertebrates, and the Gly-to-Glu change is physicochemically nonconservative. We used a battery of predictive tests to evaluate whether G138E has an impact on K5 structure and function (Supplementary Table 5 ). Not all tests agreed, but the consensus was that G138E is probably damaging. Panther, for example, returned a probability of 96.6% that the substitution is deleterious. Evidence that D197E affects protein structure was less clear cut, whereas evidence for an effect of G543S was weak (Supplementary Table 5) .
Some rare mutations affecting the basal cell keratins K5 and K14 cause epidermolysis bullosa (EB), a blistering condition in which the basal cell layer ruptures and breaks away from the underlying dermis 10 . Various forms of EB exist, ranging from mild blistering conditions to lethal failures of dermatogenesis. As with all keratins, K5 consists of a central a-helical rod flanked by nonhelical head and tail domains. EB mutations tend to cluster around the helix-initiating and helix-terminating regions at either end of the rod 10 . The G138E and D197E variants both occur in the helix-initiating region (Supplementary Fig. 1 ). The two variants were originally discovered during linkage searches for EB mutations but were discounted as neutral polymorphisms 11 . However, subsequent reports indicate that when G138E and D197E occur as compound heterozygotes with high-penetrance EB mutations, they may be associated with a more extreme EB phenotype 12, 13 .
A second BCC predisposition locus was identified in the LD block on 9p21 containing the cyclin-dependent kinase inhibitor genes CDKN2A and CDKN2B, the ARF tumor suppressor encoded by CDKN2A and the noncoding RNA ANRIL 14,15 ( Fig. 1 and Table 1 ). CDKN2A is well known for its involvement in familial melanoma 16 . Curiously, no risk of CM was associated with rs2151280, and we saw no evidence of an association with risk of SCC ( Table 1) . There was no association between rs2151280 and any of the pigmentation traits tested (Supplementary Table 3 ).
Previous reports indicated that rs10757278 in the CDKN2A/B LD block predisposes to coronary artery disease (CAD) (Fig. 1) 17 . Another SNP nearby (rs10811661) is associated with type 2 diabetes (T2D) [18] [19] [20] . The LD relationships between these SNPs and the BCC SNP rs2151280 are shown in Supplementary Table 6 . We genotyped rs10757278 and rs10811661 in the Icelandic BCC case-control set. Similarly, we investigated our CAD and T2D GWAS data 17, 21 for associations with rs2151280. The CAD SNP rs10757278 and the T2D SNP rs10811661 showed no association with BCC risk, and the BCC SNP rs2151280 was not associated with risk of T2D (Supplementary Table 7 ). The rs2151280[C] allele showed a nominal association with reduced risk of CAD (OR ¼ 0.91, P ¼ 1.3 Â 10 À3 ) but this signal disappeared after adjustment for rs10757278 (residual P ¼ 0.42; Supplementary Table 7 ). The simplest interpretation of these findings is that three distinct signals exist conferring separate risks of BCC, CAD and T2D. This implies that, in addition to the high-penetrance melanoma susceptibility variants in CDKN2A, at least three independent causative variants are present at 9p21, each having a quite distinct phenotypic effect. A third new BCC susceptibility locus was tagged by rs157935 on 7q32 within fragile site FRA7H 22 . On replication, the T allele gave an OR of 1.23 (P ¼ 5.7 Â 10 À10 ) ( Table 1) . The SNP showed no association with CM, SCC or pigmentation traits ( Table 1 and  Supplementary Table 3 ). The closest RefSeq gene is KLF14, encoding a Kruppel-like transcription factor that shows monoallelic maternal expression 23 . KLF14 is 167 kb proximal to rs157935 and is separated from it by a region of high recombination. To investigate a possible effect of imprinting on the pattern of risk, we used the Icelandic genealogy and long-range phasing 24 to determine the parent-of-origin of the rs157935 alleles inherited by the Icelandic subjects who had been typed on the Illumina platform (see Online Methods). The relative risk of the T allele was estimated as 1.40 (P ¼ 1.5 Â 10 À6 ) when inherited paternally but only 1.09 (and not significant) when inherited maternally ( Table 1) . As a direct test of whether the effect of the T allele depends significantly on parent-of-origin, we observed that 237 heterozygous cases had inherited the T allele paternally whereas only 182 had inherited the T allele maternally (P ¼ 9.6 Â 10 À3 ; see Online Methods). These results suggest that the increased BCC risk occurs mainly or exclusively through paternal transmission of the risk allele and is probably related to the imprinting at this locus. The rs157935 LD block contains microRNAs miR-29a and miR-29b-1, which include DNA methyltransferases among their targets 25 . Further investigation of this locus is warranted, and any mechanistic model should consider that, although KLF14 is expressed from the maternal allele, the increased BCC risk seems to associate with the paternal allele.
A nsSNP in SLC45A2 (previously MATP) has recently been shown to confer susceptibility to melanoma in Spanish and French populations 5, 6 . The risk variant is the common reference allele of L374F (rs16891982) and is highly associated with fair pigmentation in Europeans 26 . Here we confirmed the association with fair pigmentation using samples from Iceland, Eastern Europe, Spain and the United States, observing strong associations with all traits except red hair and freckles (Supplementary Table 3 ). We also confirmed the association with CM risk, noting that the OR was lower in Iceland than abroad (P het for Icelandic versus non-Icelandic samples ¼ 0.059, I 2 ¼ 72%; Table 3 ). We have previously remarked that other pigmentation-associated variants tend to confer less relative risk of CM in Iceland than in other countries 3 . This may be a result of little sun exposure among Icelanders. In line with the notion that variants associated with both CM and pigmentation traits are expected to confer cross-risk of nonmelanoma skin cancers, we found that L374F also confers significant risk of BCC and SCC (Table 3) . Again, we noted that the effect of the variant on BCC risk in Iceland was less than abroad (P het for Icelandic versus non-Icelandic samples ¼ 5.0 Â 10 À3 , I 2 ¼ 87%; Table 3 ). We previously reported that rs401681 in the TERT-CLPTM1L locus affects risk of BCC and other cancers 4 . We also discovered evidence that the BCC risk allele rs401681[C] confers protection against CM. Here we sought to confirm this observation by typing additional CM casecontrol samples from Holland, Austria and Italy and larger control sample numbers from Iceland, Sweden and Spain ( Table 4) . Combined data from only the three new case-control sample sets revealed an OR for CM of 0.83 (P ¼ 9.4 Â 10 À5 ) for the rs401681[C] allele, providing an independent confirmation of the initial finding ( Table 4) . Combining all the samples tested, the OR for CM was estimated as 0.86 (P ¼ 5.0 Â 10 À8 ). Typing additional BCC samples from Spain and the United States also provided independent confirmation of the association with BCC, albeit with a considerably lower OR than observed in Iceland ( Table 4) . There was no evidence from the combined Icelandic and US sample data to support an association of rs401681 with SCC.
The rs401681[C] allele may be associated with an acceleration of the gradual shortening of telomeres with age 4 . Shorter telomeres in peripheral blood cells have been associated with an increased risk of BCC whereas longer telomeres are a risk factor for CM and nevi 27, 28 . This is probably related to the different roles of replicative senescence in basal keratinocytes and melanocytes 27 . The inverse relationship between rs401681[C] and risks of BCC and CM is perhaps reflective of this difference.
To evaluate the impact of known common variants on the risk of BCC, we determined the joint population attributable risk (PAR; see Online Methods). Even without including the high-frequency SLC45A2 variant, we estimate a joint PAR of 74% for the BCC susceptibility loci we report here together with the previously known BCC susceptibility variants in ASIP, TYR, MC1R, 1p36, 1q42 and TERT-CLPTM1L 1,3,4 (Supplementary Table 8 ). Thus, these sequence variants have some role in most cases of BCC.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. GenBank: KRT5, NP_000415; KRT5 mRNA, NM_000424; SLC45A2, NP_001012527; ANRIL, DQ485453.
Note: Supplementary information is available on the Nature Genetics website. 
ONLINE METHODS
Subjects. Approval for the study was granted by the Icelandic National Bioethics Committee, the Icelandic Data Protection Authority and by local ethics committees for each of the non-Icelandic replication sample sets. The sample sets from Iceland, Eastern Europe, United States, Sweden and the Spanish CM cases and controls have been described previously (see Supplementary Table 1 ). All Icelandic BCC, SCC and CM cases had histologically confirmed diagnoses recorded by the Icelandic Cancer Registry, which has a nationwide catchment. Spain BCC. BCC cases were recruited from the Oncology Department of Zaragoza Hospital between September 2007 and December 2008. Individuals with histologically proven invasive BCC were eligible to participate in the study. The median time interval from BCC diagnosis to collection of blood samples was 14 months (range 1-53 months). Median age at diagnosis was 69 years (range 21-91).
Holland CM. Individuals diagnosed with melanoma of the skin (ICD-O-3 code C44 and C80, morphology codes 8720-8790) in the period [2003] [2004] [2005] [2006] [2007] were identified in the regional cancer registry held by the Comprehensive Cancer Centre East in Nijmegen, The Netherlands. This cancer center keeps a population-based cancer registry and covers the eastern part of the Netherlands, a region with 1.3 million inhabitants, one university clinic and seven community hospitals. All individuals diagnosed with melanoma at or before the age of 75 were invited to participate in the study. The invitation was done by the subjects' treating physicians (dermatologists and general or plastic surgeons) who all agreed to collaborate in this study. Informed consent was obtained for the collection of questionnaire data on lifestyle including sun exposure, medical history and family history, the collection of two 10 ml blood samples, possible linkage to population and disease registries (cancer registry, mortality registry, hospital information systems and the Dutch demographic register), collection of additional clinical data from their medical records, and the retention of identifying information for a duration of 25 years. The Comprehensive Cancer Centre East collects clinical and pathology data of all subjects in the cancer registry. In The Netherlands, lifestyle information, family history of cancer, reproductive and medical history as well as blood samples are available from a group of 6,700 population controls. These controls were collected in a survey in 2002-2003 by the Radboud University Nijmegen Medical Centre. This survey, The Nijmegen Biomedical Study, was based on an age-stratified random sample of the population of Nijmegen. From this group 1,832 male and female control individuals were selected and genotyped. Similar informed consent as described above was obtained from these controls.
Austria CM. After obtaining written informed consent, individuals attending the outpatient ward of the Department of Dermatology, Medical University of Vienna were invited to participate in the project. Subjects donated 3.4 ml of peripheral blood for DNA extraction. Information regarding skin phototype, sun exposure history and prior malignancies was assessed by interview questionnaire and from clinical records. In addition to the questionnaire, photographic documentation of the eyes, hair, back and arms (for assessment of nevi and sun exposure-related damage) was performed. Controls were recruited from individuals attending the Department of Dermatology for nonmelanoma-related conditions. All subjects were of self-reported Austrian or central European descent. All samples and data were coded and archived anonymously. Genotyping. All Icelandic samples were typed using Illumina HumanHap300 or HumanCNV370-duo chips or by Nanogen Centaurus single-track genotyping assays as described previously 1 . For BCC, 930 Icelandic cases were typed on Illumina chips and the remaining 903 samples were typed by Centaurus assay. For non-Illumina SNPs, approximately 1,690 Icelandic BCC cases and 2,456 controls were genotyped using Centaurus assay. Primer sequences for Centaurus assays are available on request. Centaurus SNP assays were validated by genotyping the HapMap CEU samples and comparing genotypes with the published data. Assays were rejected if they showed 41.5% mismatches with the HapMap data. Approximately 10% of Icelandic case samples that were genotyped on the Illumina platform were also genotyped using the Centaurus assays and the observed mismatch rate was less than 0.5%. All samples from foreign cohorts were typed using the same Centaurus assays at the deCODE Genetics facility. Clustering algorithms were applied and manual editing was carried out in the same way as for the Icelandic samples. Two standard DNA samples and water blanks were included on every plate. Heterogeneity tests were used to monitor for deviant results originating from particular cohorts and the P het values are shown in the relevant results tables.
Statistical analysis. We calculated the OR for each SNP allele or haplotype assuming the multiplicative model, that is, that the relative risks of the two alleles that a person carries multiply. Allelic frequencies and OR are presented for the markers. The associated P values were calculated with the standard likelihood ratio w 2 statistic. Confidence intervals were calculated assuming that the estimate of OR has a log-normal distribution. For SNPs that were in strong LD, whenever the genotype of one SNP was missing for an individual, the genotypes of the correlated SNPs were used to impute genotypes through a likelihood approach as previously described 1 . Some of the Icelandic cases and controls are related to each other, causing the w 2 statistic to have a mean 41. We estimated the inflation factor by simulating genotypes through the Icelandic genealogy and corrected the w 2 statistics for Icelandic OR's accordingly. The correction factors used were 1.20 for BCC, 1.07 for CM, 1.05 for SCC, 1.21 for CAD and 1.33 for T2D. Joint analyses of multiple case-control replication groups were carried out using a Mantel-Haenszel model in which the groups were allowed to have different population frequencies for alleles or genotypes but were assumed to have common relative risks. The tests of heterogeneity were performed by comparing the null hypothesis of the effect being the same in all populations to the alternative hypothesis of each population having a different effect using a likelihood ratio test. I 2 lies between 0% and 100% and describes the proportion of total variation in study estimates that is due to heterogeneity 29 . We calculated genotype-specific ORs by estimating the genotype frequencies in the population assuming Hardy-Weinberg equilibrium. No significant deviations from the multiplicative model were observed, all P values being 40.05.
The population attributable risk (PAR) was calculated for each of nine variants as follows:
) where P ¼ frequency of the risk allele (estimated as the arithimetic average of the frequencies in each of the constituent population samples) and OR ¼ allelic odds ratio for the risk allele (combined from the constituent population samples using The Mantel-Haenszel method).
The joint population attributable risk (Joint PAR) for combinations of variants was calculated as follows:
) where PAR i corresponds to the individual PAR for the ith SNP and n is the number of variants considered. The full genotype-specific model did not provide a signficiantly better fit of the data than the multiplicative model for the variants reported here and for the variants previously reported 1, 3 ; therefore, we used the multiplicative model in determination of PAR. There was no significant heterogeneity in allele effect between constituent populations. To search for potential epistatic interactions, all pairwise combinations of the nine variants (a total of 36 tests) were tested using logistic regression, comparing models with and without an interaction term. The lowest P value we obtained for any pairwise interaction was 0.03, which is not significant once the number of tests conducted is taken into account. Therefore, we assumed no epistatic interactions between loci in our calculation of joint PAR.
Combining the Icelandic genealogy and the method of long-range phasing 24 allowed us to determine the parental origins of the haplotypes in most of the Icelanders who were typed using an Illumina chip. In particular, long-range phasing was accomplished through identifying individuals who shared a long haplotype (identical by descent) with the proband, people referred to as surrogate parents. In general, there would be a group of surrogate parents for one haplotype and another group for the other haplotype, although in some cases, only surrogate parents for one of the two haplotypes could be identified. For each haplotype of the proband, we determined, using the genealogy, the shortest meiotic distance to a surrogate parent through the father (minimum paternal distance) and the shortest distance through the mother (minimum maternal distance). For example, if the minimum paternal distance is substantially less than the minimum maternal distance, then the haplotype is likely to be inherited paternally. Moreover, the parental origins of the two haplotypes can be reliably determined if strong evidence exists for one of the two haplotypes. In general, a score is created by combining the results from both haplotypes. For the 1,118 cases and 34,869 controls in the BCC parent-of-origin analysis, only ten rs157935 heterozygotes in cases and 335 heterozygotes in controls had undetermined parental origins. To avoid bias, we included these individuals to estimate frequencies of the T allele in parental and maternal chromosomes for cases and controls, and likelihood approaches were used to properly take the incomplete information into account. Maximum likelihood and likelihood ratio tests were used to test/estimate the effect of the T allele when transmitted paternally and when transmitted maternally. To directly test whether the T allele confers an effect that depends on parental origin, we tested whether the number of ordered TG (first allele paternal, second allele maternal) heterozygotes (237) within the cases is greater than the number of ordered GT heterozygotes (182). If there is no parent-of-origin effect, then the two counts should be the same, in expectation. A binomial test gave a two-sided P of 0.0083. Even though stratification is not an issue here, a variance adjustment is still needed to account for relatedness. Using genomic control, we converted the binomial P to a 1-d.f. w 2 statistic and divided it by 1.04, the adjustment factor, resulting in a P of 0.0096. By contrast, the number of TG heterozygotes and GT heterozygotes in controls showed no significance difference (7,452 versus 7,419, P ¼ 0.80). All P values are reported as two-sided.
URLs. Locations of epidermolysis bullosa variants and domain definitions for K5 were derived from the Human Intermediate Filament Database, http:// www.interfil.org 30 .
